Navigation Links
PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Date:12/9/2010

ANNAPOLIS, Md., Dec. 9, 2010 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that the United States Food and Drug Administration (FDA) has provided formal consent for PharmAthene to reinitiate clinical testing of its anthrax anti-toxin, Valortim®, after lifting the partial clinical hold placed on the program in late 2009.

"We're very pleased to resume clinical testing of Valortim®," remarked Dr. Thomas Fuerst, Senior Vice President and Chief Scientific Officer.  "The accumulating data suggest that Valortim® may have unique characteristics, which could position it as a leading candidate for future procurement in the nation's biodefense stockpile.  A presumed different mechanism of action, relative to other anthrax monoclonal antibodies and encouraging efficacy data in animal studies at low doses, suggest that Valortim® may offer important advantages in the treatment of symptomatic anthrax infection."

Dr. Fuerst continued, "We have proposed moving forward with a Phase I intravenous dose-escalation study of Valortim®, which is expected to commence in the next several weeks.  We look forward to resuming clinical testing of this important anthrax anti-toxin candidate, which we hope one day will offer improved protection for our nation's citizens, both at home and on the battlefield."

Valortim® is a fully human anti-toxin monoclonal antibody being developed for the prevention and treatment of inhalational anthrax.  Animal studies suggest that Valortim® has the potential to provide protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident).

The Valortim® project has been funded in whole or in part with Federal f
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
2. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
3. PharmAthene Announces Pricing of $15 Million Public Offering
4. PharmAthene Announces Proposed Common Stock Offering
5. PharmAthene Announces $3.9 Million Registered Direct Offering
6. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
7. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
8. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
9. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
10. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
11. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Whitefox ( http://www.whitefox.com ... has signed an agreement with  California ... the delivery of an industrial scale membrane system. The ... water, energy and emissions in the production ... project is fully aligned with ...
(Date:5/6/2015)... OR (PRWEB) May 06, 2015 ... search and growth strategy for the specialty pharmacy industry, ... of the 2015 Armada Specialty Pharmacy Summit. The Summit ... Hotel in Las Vegas and is the largest annual ... will be in attendance, from pharmacy providers, pharma/biotech manufacturers, ...
(Date:5/5/2015)... SAN DIEGO AND TORONTO, May 5, 2015 /PRNewswire/ - Aptose ... "Company") today reported financial results for the three months ... Unless specified otherwise, all amounts are in Canadian dollars. ... changed its fiscal year end from May 31 to ... current interim period being reported is for the three ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 ... Life Science Animal Health, Jeffrey Schaffer, DVM, as ... “With over 15 years of experience in the ... a great addition to our veterinarian lead organization”. ... Officer, explains. “Dr. Schaffer will be responsible for ...
Breaking Biology Technology:Whitefox Signs Agreement With Pacific Ethanol Inc. 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2
... Patients, ... Aug. 22 Today, a new grassroots,ballot initiative was launched ... without involving human cloning. Tony Perkins, the President of ... Cures Without Cloning. "I applaud the new Missouri initiative ...
... The U.S. Food and Drug,Administration (FDA) today ... adolescents ages 13-17 and for the short-term,treatment of ... of,bipolar I disorder in children and adolescents ages ... involving more than 430 adolescents,ages 13-17, in the ...
... overall growth in cosmetics and ... toiletries market -, LITTLE FALLS, ... convince Europeans of the importance of,better oral care appears to have paid ... according to a newly published study by global,management consulting and market research ...
Cached Biology Technology:FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania 2FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania 3Kline Study: Better Brushing Habits Boost European Oral Care Sales 2Kline Study: Better Brushing Habits Boost European Oral Care Sales 3
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... N.J. The National Science Foundation (NSF), in collaboration ... awarded Rutgers University two grants to lead research on ... terrorists from using such materials to develop dirty bombs ... the population and paralyze commerce. The NSF has ...
... questions (media only), contact: Emma Mason, ECCO 14 media ... 986, email: wordmason@mac.com ,or Mary Rice, FECS media ... 304 8897, email: mary@mrcommunication.org , Any enquiries about ... to the FECS office ( www. ,Only a few ...
... study published in Nature Genetics on Sunday 16 September 2007 ... due to genetic variation in regions that control activity of ... code. This surprising result comes from a study at ... 14,000 genes in 270 DNA samples collected for the HapMap ...
Cached Biology News:Homeland Security awards 2 grants to Rutgers for nuclear threat detection 2Homeland Security awards 2 grants to Rutgers for nuclear threat detection 3Last chance for media to register for ECCO 14 -- the European Cancer Conference 2Last chance for media to register for ECCO 14 -- the European Cancer Conference 3The importance of gene regulation for common human disease 2
... Tecans state-of-the-art software for all your biopharmaceutical ... in a single, scalable software package. The ... simplifying the control of all Freedom instruments ... EVO 100 with one liquid handling arm ...
... Kit is an advanced system for isolating DNA from ... be used directly for any downstream application. ... to use in 56 minutes Low melting point ... and TBE gels No specialised equipment required ...
... in hybridization incubators with rotators. Graduated, ... size PP plug-seal screw-cap with O-ring ... three lengths to accept different size ... O-rings available separately. • Comp Dim: ...
... efficient extraction of DNA fragments from 150 bp to ... procedure uses GelMelt solution to dissolve the gel slice, ... membrane in a spin column format. After a wash ... Each spin column can bind up to 20 g ...
Biology Products: